Novonesis downgraded to Sell from Neutral at Citi

Citi analyst Ranulf Orr downgraded Novonesis to Sell from Neutral with a price target of DKK 400, up from DKK 390. The company’s mid-term growth expectations are unlikely to be achieved, the analyst tells investors in a research note.